Oxygen Biotherapeutics, Inc. OXBT today announced that it has
entered into definitive agreements with an institutional investor for a
financing of up to $2.1 million in gross proceeds. Under the terms of the
agreements, Oxygen will issue registered shares of Series B-1 convertible
preferred stock (the “Series B-1 Stock”) for $1.6 million in gross proceeds
and unregistered shares of Series B-2 convertible preferred stock (the “Series
B-2 Stock” and, together with the Series B-1 Stock, the “Preferred Stock”) for
$0.5 million in gross proceeds, which are convertible into common stock of the
Company at $0.25 per share. The transaction also provides for the issuance by
the Company of unregistered warrants to purchase up to 12,600,000 shares of
common stock of the Company with an initial exercise price of $0.50.
The offering is expected to close on or about Wednesday, February 27, 2013,
subject to the satisfaction of customary closing conditions. A more complete
description of the terms and conditions of the financing will be available in
the Form 8-K to be filed by the Company with the Securities and Exchange
Commission (the “SEC”).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in